利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.044 秒)

    Gene signature for predicting prognosis of patients with solid tumors
    1.
    发明授权
    Gene signature for predicting prognosis of patients with solid tumors 有权
    用于预测实体瘤患者预后的基因特征

    公开(公告)号：US08735082B2

    公开(公告)日：2014-05-27

    申请号：US13127701

    申请日：2009-11-10

    申请人： Xin Wei Wang ,  Stephanie K. Roessler

    发明人： Xin Wei Wang ,  Stephanie K. Roessler

    IPC分类号： G01N33/574

    CPC分类号： C07K16/18 ,  C12N15/113 ,  C12N15/85 ,  C12N15/86 ,  C12Q1/6841 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57438 ,  G01N2800/50

    摘要： Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor-associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins.

    摘要翻译： 本文公开了用于预测实体瘤患者如肝细胞癌（HCC）和乳腺癌的存活的驱动基因特征。 基因特征包括10个肿瘤相关基因SH2D4A，CCDC25，ELP3，DLC1，PROSC，SORBS3，HNRPD，PAQR3，PHF17和DCK。 实体瘤中SH2D4A，CCDC25，ELP3，DLC1，PROSC和SORBS3的DNA拷贝数或mRNA表达降低与预后不良相关，而HNRPD，PAQR3，PHF17和DCK的DNA拷贝数或mRNA表达降低 实体瘤有良好的预后。 因此，本文提供了通过检测肿瘤样品中更多肿瘤相关基因之一的表达并比较肿瘤中一种或多种肿瘤相关基因的表达来预测诊断为HCC或乳腺癌的患者的预后的方法 样本到控件。 还提供了通过施用治疗有效量的改变一种或多种所公开的肿瘤相关基因的表达或活性的药剂来治疗被诊断患有HCC或乳腺癌的患者的方法。 还提供了包含针对多个肿瘤相关基因或蛋白质特异的探针或抗体的阵列。

    Compositions and methods for diagnosis and treatment of tumors
    2.
    发明授权
    Compositions and methods for diagnosis and treatment of tumors 失效
    用于诊断和治疗肿瘤的组合物和方法

    公开(公告)号：US08568977B2

    公开(公告)日：2013-10-29

    申请号：US13549633

    申请日：2012-07-16

    申请人： Vivian Takafuji ,  Xin Wei Wang ,  Paul K. Goldsmith

    发明人： Vivian Takafuji ,  Xin Wei Wang ,  Paul K. Goldsmith

    IPC分类号： C12Q1/68 ,  G01N33/53

    CPC分类号： C07K16/2848 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/24 ,  C07K16/2884 ,  C07K16/40 ,  C07K2317/76 ,  G01N33/57438 ,  G01N33/57484 ,  G01N2333/52

    摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5kD and antibodies specific for OPN-5kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5kD.

    摘要翻译： 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用而引起的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。

    GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS
    3.
    发明申请
    GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS 有权
    用于预测患有固体肿瘤的患者的基因标志

    公开(公告)号：US20110206703A1

    公开(公告)日：2011-08-25

    申请号：US13127701

    申请日：2009-11-10

    申请人： Xin Wei Wang ,  Stephanie K. Roessler

    发明人： Xin Wei Wang ,  Stephanie K. Roessler

    IPC分类号： A61K39/395 ,  C40B30/04 ,  A61K31/7088 ,  A61P35/00

    CPC分类号： C07K16/18 ,  C12N15/113 ,  C12N15/85 ,  C12N15/86 ,  C12Q1/6841 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57415 ,  G01N33/57438 ,  G01N2800/50

    摘要： Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor-associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins.

    摘要翻译： 本文公开了用于预测实体瘤患者如肝细胞癌（HCC）和乳腺癌的存活的驱动基因特征。 基因特征包括10个肿瘤相关基因SH2D4A，CCDC25，ELP3，DLC1，PROSC，SORBS3，HNRPD，PAQR3，PHF17和DCK。 实体瘤中SH2D4A，CCDC25，ELP3，DLC1，PROSC和SORBS3的DNA拷贝数或mRNA表达降低与预后不良相关，而HNRPD，PAQR3，PHF17和DCK的DNA拷贝数或mRNA表达降低 实体瘤有良好的预后。 因此，本文提供了通过检测肿瘤样品中更多肿瘤相关基因之一的表达并比较肿瘤中一种或多种肿瘤相关基因的表达来预测诊断为HCC或乳腺癌的患者的预后的方法 样本到控件。 还提供了通过施用治疗有效量的改变一种或多种所公开的肿瘤相关基因的表达或活性的药剂来治疗被诊断患有HCC或乳腺癌的患者的方法。 还提供了包含针对多个肿瘤相关基因或蛋白质特异的探针或抗体的阵列。

    COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
    4.
    发明申请
    COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS 有权
    用于诊断和治疗肿瘤的组合物和方法

    公开(公告)号：US20100322950A1

    公开(公告)日：2010-12-23

    申请号：US12871669

    申请日：2010-08-30

    申请人： VIVIAN TAKAFUJI ,  XIN WEI WANG ,  EDWARD J. UNSWORTH ,  PAUL K. GOLDSMITH

    发明人： VIVIAN TAKAFUJI ,  XIN WEI WANG ,  EDWARD J. UNSWORTH ,  PAUL K. GOLDSMITH

    IPC分类号： A61K39/395 ,  G01N33/53 ,  C12Q1/68 ,  C12N5/00 ,  C12N5/16 ,  C07K16/18 ,  C07H21/04 ,  C12N15/63 ,  C12N1/21 ,  C12N5/10 ,  C12N1/19 ,  A61P35/00 ,  G01N33/00

    CPC分类号： C07K16/2848 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/24 ,  C07K16/2884 ,  C07K16/40 ,  C07K2317/76 ,  G01N33/57438 ,  G01N33/57484 ,  G01N2333/52

    摘要： Based on the observation of the cooperation of osteopontin (OPN) and matrixmetalloproteinase-9 (MMP-9) in the promotion of the metastatic phenotype, therapies and diagnostic assays are disclosed for the treatment of a tumor that overexpresses OPN, such as hepatocellular carcinoma (HCC), for example metastatic HCC. In one example, methods of treating a tumor include administration of an agent that reduces cellular invasion resulting from the interaction between a fragment of OPN (OPN-5 kD) generated by MMP-9 cleavage and CD44 receptor. Examples of such agents include fragments of OPN-5 kD and antibodies specific for OPN-5 kD. Therapeutic compositions are also provided that include such agents. Also provided are methods of diagnosing or prognosing a tumor, for example by detecting expression of OPN-5 kD peptide or OPN-c mRNA in a biological sample obtained from the subject. Also provided are antibodies that specifically bind OPN-5 kD.

    摘要翻译： 基于骨桥蛋白（OPN）和基质金属蛋白酶-9（MMP-9）在促进转移表型中的合作观察，公开了治疗和过度表达OPN的肿瘤如肝细胞癌（ HCC），例如转移性HCC。 在一个实例中，治疗肿瘤的方法包括施用减少由MMP-9切割产生的OPN片段（OPN-5kD）与CD44受体之间的相互作用导致的细胞侵袭的药剂。 这些试剂的实例包括OPN-5kD片段和OPN-5kD特异性抗体。 还提供包括这些试剂的治疗组合物。 还提供了诊断或预后肿瘤的方法，例如通过检测从受试者获得的生物样品中OPN-5kD肽或OPN-cmRNA的表达。 还提供了特异性结合OPN-5kD的抗体。

    Screening assays for compounds that cause apoptosis
    6.
    发明授权
    Screening assays for compounds that cause apoptosis 失效
    导致凋亡的化合物的筛选试验

    公开(公告)号：US07338807B2

    公开(公告)日：2008-03-04

    申请号：US10633789

    申请日：2003-08-04

    申请人： Curtis C. Harris ,  Xin Wei Wang ,  Jan H. J. Hoeijmakers

    发明人： Curtis C. Harris ,  Xin Wei Wang ,  Jan H. J. Hoeijmakers

    IPC分类号： G01N33/00

    CPC分类号： A61K38/1709 ,  C07K14/4746 ,  C07K2319/00

    摘要： This invention relates to methods of screening for compounds capable of inducing apoptosis in certain tumor cells. The invention also relates to compounds identified by such methods. In addition, the invention relates to methods for the in vitro diagnosis of Xeroderma pigmentosum and compounds useful in these methods.

    摘要翻译： 本发明涉及筛选能够诱导某些肿瘤细胞凋亡的化合物的方法。 本发明还涉及通过这些方法鉴定的化合物。 此外，本发明涉及用于这些方法中有用的皮肤色素调色剂和化合物的体外诊断方法。

    Card edge connector
    8.
    发明授权
    Card edge connector 失效
    卡缘连接器

    公开(公告)号：US08771001B2

    公开(公告)日：2014-07-08

    申请号：US13568134

    申请日：2012-08-07

    申请人： Zhuang-Xing Li ,  Xin-Wei Wang ,  Xue-Wu Bu

    发明人： Zhuang-Xing Li ,  Xin-Wei Wang ,  Xue-Wu Bu

    IPC分类号： H01R13/639

    CPC分类号： H01R13/639 ,  H01R12/7029 ,  H01R12/721

    摘要： A card edge connector (100) includes an elongated housing (1) and a plurality of contacts (2). The housing (1) has two side walls (103) and a central slot (109) between the two side walls (103) for receiving a memory module (9). The card edge connector (100) includes a latching mechanism (5) mounted on the two side walls (103) for resisting the memory module (9) downwardly. The latching mechanism (5) can prevent the memory module (9) from moving upwardly, thereby the memory module (9) could be stably connected with the card edge connector (100).

    摘要翻译： 卡缘连接器（100）包括细长壳体（1）和多个触点（2）。 壳体（1）在两个侧壁（103）之间具有两个侧壁（103）和中间槽（109），用于接收存储模块（9）。 卡边缘连接器（100）包括安装在两个侧壁（103）上的用于向下抵抗存储模块（9）的锁定机构（5）。 锁定机构（5）可以防止存储器模块（9）向上移动，由此存储器模块（9）可以与卡缘连接器（100）稳定连接。

    CARD EDGE CONNECTOR HAVING IMPROVED EJECTOR
    9.
    发明申请
    CARD EDGE CONNECTOR HAVING IMPROVED EJECTOR 有权
    具有改进的喷射器的卡边缘连接器

    公开(公告)号：US20130095679A1

    公开(公告)日：2013-04-18

    申请号：US13651488

    申请日：2012-10-15

    申请人： ZHUANG-XING LI ,  XUE-HAI SHEN ,  XIN-WEI WANG ,  XUE-WU BU

    发明人： ZHUANG-XING LI ,  XUE-HAI SHEN ,  XIN-WEI WANG ,  XUE-WU BU

    IPC分类号： H01R13/62

    CPC分类号： H01R12/7005

    摘要： A card edge connector (100) includes an insulative housing, a set of contacts (2) retained in the insulative housing and an ejector (3). The insulative housing has a central slot (12) and one tower portion (13) having a receiving slot (135). The contacts protrude into the central slot. The ejector has a main portion (31) received in the receiving slot, an ejecting portion (34) extending from a lower end (35) of the main portion, a locking portion (32) extending inwardly from an upper end of the main portion, and a lever portion (37) extending outwardly from the upper end of the main portion. The locking portion has a pair of vertical portions (324), and a transverse portion (323). The transverse portion connects the vertical portions and divides the vertical portions into upper and lower retaining parts.

    摘要翻译： 卡缘连接器（100）包括绝缘壳体，保持在绝缘壳体中的一组触点（2）和喷射器（3）。 绝缘壳体具有中心槽（12）和一个具有接收槽（135）的塔架部分（13）。 触点突出到中心插槽中。 喷射器具有容纳在容纳槽中的主要部分（31），从主体部分的下端（35）延伸的喷射部分（34），从主体部分的上端向内延伸的锁定部分 ，以及从主体部的上端向外延伸的杆部（37）。 锁定部分具有一对垂直部分（324）和横向部分（323）。 横向部分连接垂直部分并将垂直部分分成上部和下部保持部分。